doctor pbm glp-1 approval process Glucagon-like peptide-1 receptor: mechanisms and advances in therapy GLP-1 medications may not work

They revealed that the glucagon precursor gene encoded additional peptides beyond glucagon [6,7]

CRISPR: The Platform Patent Dispute and Its Commercial Consequences CRISPR-Cas9 gene editing technology is subject to one of the most intensely litigated platform patent disputes in history, between the Broad Institute (controlling IP developed in Zhang Fengs laboratory) and the University of California (controlling IP from Jennifer Doudna and Emmanuelle Charpentiers work)

CGI-S, Clinical Global Improvement-severity

This study cannot prove that GLP-1 drugs directly cause bone loss, but it raises important questions, especially for older adults already at risk for osteoporosis

D.ZhaoZ.MontagneA.NelsonA